Catalyst Pharmaceutical Partners Inc., of Coral Gables, Fla., said the independent data monitoring committee recommended that the ongoing pivotal phase III trial of Firdapse for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) continue as planned following a review of safety and clinical data.